Your browser doesn't support javascript.
loading
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.
O'Byrne, Paul M; Metev, Hristo; Puu, Margareta; Richter, Kai; Keen, Christina; Uddin, Mohib; Larsson, Bengt; Cullberg, Marie; Nair, Parameswaran.
Afiliación
  • O'Byrne PM; Firestone Institute for Respiratory Health, St Joseph's Healthcare and McMaster University, Hamilton, ON, Canada. Electronic address: obyrnep@mcmaster.ca.
  • Metev H; SHATPPD-Ruse EOOD, Ruse, Bulgaria.
  • Puu M; AstraZeneca R&D, Gothenburg, Sweden.
  • Richter K; AstraZeneca R&D, Gothenburg, Sweden.
  • Keen C; AstraZeneca R&D, Gothenburg, Sweden.
  • Uddin M; AstraZeneca R&D, Gothenburg, Sweden.
  • Larsson B; AstraZeneca R&D, Gothenburg, Sweden.
  • Cullberg M; AstraZeneca R&D, Gothenburg, Sweden.
  • Nair P; Firestone Institute for Respiratory Health, St Joseph's Healthcare and McMaster University, Hamilton, ON, Canada.
Lancet Respir Med ; 4(10): 797-806, 2016 10.
Article en En | MEDLINE | ID: mdl-27574788
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Pirimidinas / Asma / Sulfonamidas / Corticoesteroides / Antiasmáticos Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Respir Med Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Pirimidinas / Asma / Sulfonamidas / Corticoesteroides / Antiasmáticos Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Respir Med Año: 2016 Tipo del documento: Article